Association between plasma levels of plasminogen activator inhibitor-1 and colorectal neoplasms

Gut and Liver

Volumn 7, Issue 5, 2013, Pages 519-523

  Kim, Eun Ran ^a   Yang, Mun Hee ^a   Lim, Yeun Jung ^a   Lee, Jin Hee ^a   Chang, Dong Kyung ^a   Kim, Young Ho ^a   Son, Hee Jung ^a   Kim, Jae J ^a   Rhee, Jong Chul ^a   Kim, Jin Yong ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Colorectal neoplasms; Plasminogen activator inhibitor 1

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; BLOOD LEVEL; BODY MASS; COLONOSCOPY; COLORECTAL ADENOMA; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; REVIEW;

EID: 84884747335     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2013.7.5.519     Document Type: Review

References (21)

1. McMahon B, Kwaan HC. The plasminogen activator system and cancer. Pathophysiol Haemost Thromb 2008;36:184-194.
2. Bajou K, Noël A, Gerard RD, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998;4:923-928. (Pubitemid 28364031)
3. Sier CF, Verspaget HW, Griffioen G, et al. Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis. Gastroenterology 1991;101:1522-1528.
4. Papadopoulou S, Scorilas A, Yotis J, et al. Significance of urokinase- type plasminogen activator and plasminogen activator inhibitor-1 (PAI-1) expression in human colorectal carcinomas. Tumour Biol 2002;23:170-178. (Pubitemid 44858308)
5. Nilsson L, Banfi C, Diczfalusy U, Tremoli E, Hamsten A, Eriksson P. Unsaturated fatty acids increase plasminogen activator inhibitor-1 expression in endothelial cells. Arterioscler Thromb Vasc Biol 1998;18:1679-1685. (Pubitemid 28521055)
6. Nilsson L, Gåfvels M, Musakka L, et al. VLDL activation of plasminogen activator inhibitor-1 (PAI-1) expression: involvement of the VLDL receptor. J Lipid Res 1999;40:913-919. (Pubitemid 29220532)
7. Liu CS, Hsu HS, Li CI, et al. Central obesity and atherogenic dyslipidemia in metabolic syndrome are associated with increased risk for colorectal adenoma in a Chinese population. BMC Gastroenterol 2010;10:51.
8. Tabuchi M, Kitayama J, Nagawa H. Hypertriglyceridemia is positively correlated with the development of colorectal tubular adenoma in Japanese men. World J Gastroenterol 2006;12:1261-1264.
9. Baker EA, Leaper DJ. The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology. Eur J Cancer 2003;39:981-988. (Pubitemid 36428631)
10. de Bruin PA, Griffioen G, Verspaget HW, Verheijen JH, Lamers CB. Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas. Cancer Res 1987;47:4654-4657. (Pubitemid 17124643)
11. Protiva P, Sordat I, Chaubert P, et al. Alterations in plasminogen activation correlate with epithelial cell dysplasia grading in colorectal adenomas. Br J Cancer 1998;77:297-304. (Pubitemid 28029547)
12. Stefansson S, McMahon GA, Petitclerc E, Lawrence DA. Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des 2003;9:1545-1564. (Pubitemid 36763492)
13. Andreasen PA. PAI-1: a potential therapeutic target in cancer. Curr Drug Targets 2007;8:1030-1041. (Pubitemid 47578151)
14. Binder BR, Mihaly J. The plasminogen activator inhibitor paradox in cancer. Immunol Lett 2008;118:116-124.
15. Duffy MJ, Duggan C. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem 2004;37:541-548. (Pubitemid 38845017)
16. Seetoo DQ, Crowe PJ, Russell PJ, Yang JL. Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. J Surg Oncol 2003;82:184-193. (Pubitemid 36278267)
17. Försti A, Lei H, Tavelin B, et al. Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer. Ann Oncol 2007;18:1990-1994. (Pubitemid 350286237)
18. Loktionov A, Watson MA, Stebbings WS, Speakman CT, Bingham SA. Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis. Cancer Lett 2003;189:189-196. (Pubitemid 35461995)
19. Langenskiöld M, Holmdahl L, Angenete E, Falk P, Nordgren S, Ivarsson ML. Differential prognostic impact of uPA and PAI-1 in colon and rectal cancer. Tumour Biol 2009;30:210-220.
20. Nielsen HJ, Pappot H, Christensen IJ, et al. Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer. BMJ 1998;316:829-830. (Pubitemid 28112429)
21. Mutoh M, Niho N, Komiya M, et al. Plasminogen activator inhibitor- 1 (Pai-1) blockers suppress intestinal polyp formation in Min mice. Carcinogenesis 2008;29:824-829. (Pubitemid 351494171)